Vanda Pharmaceuticals Inc. — Form 10-Q
Filed August 6, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 28/100
What the filing says
Vanda Pharmaceuticals (counterparty: Square 54 Office Owner LLC) amended its lease at 2200 Pennsylvania Avenue NW, Washington DC (effective 5/1/2026). The company adds 6,845 sq ft on the 6th floor at $61.00/rsf (Dec 2026–Nov 2027, abated) and $62.53/rsf thereafter, while surrendering 9,928 sq ft on the 5th floor by 11/30/2026. The lease term extends to 7/31/2038 (10 years from 8/1/2028). Annual base rent for the renewal term (Aug 2028–Jul 2038) ranges from $2.58M to $3.23M/year. Vanda receives 11-month rent abatement on both new and renewal space.
Why this rating
Routine real-estate amendment. ~$3M annual rent is ~3–5% of a $269M market cap—material but standard for a stable pharma company. No operational or financial shock.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.